Download PDF
PSYCH up2date 2022; 16(06): 493-511
DOI: 10.1055/a-1239-5941
Schizophrenien und andere psychotische Störungen

Langzeittherapie der Schizophrenie

Maximilian Huhn
1   Klinik und Poliklinik für Psychiatrie und Psychotherapie, Klinikum rechts der Isar der Technischen Universität München, München, Deutschland (Ringgold ID: RIN27190)
,
Johannes Schneider-Thoma
1   Klinik und Poliklinik für Psychiatrie und Psychotherapie, Klinikum rechts der Isar der Technischen Universität München, München, Deutschland (Ringgold ID: RIN27190)
,
Stefan Leucht
1   Klinik und Poliklinik für Psychiatrie und Psychotherapie, Klinikum rechts der Isar der Technischen Universität München, München, Deutschland (Ringgold ID: RIN27190)
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints All articles of this category

Antipsychotika sind bei Schizophrenie essenziell in der Akutbehandlung. Für die Langzeittherapie gibt es keine klaren Empfehlungen zu Dauer und Dosierung. Das Rückfallrisiko ist unter Medikation geringer, wobei eventuelle Nebenwirkungen überwacht werden müssen. Ein abruptes Absetzen der Medikation ist unbedingt zu vermeiden. Reduktionsversuche sollten nur in kleinen Schritten erfolgen. Psychosoziale Interventionen reduzieren das Rückfallrisiko.
Kernaussagen

  • Erkrankungen aus dem schizophrenen Formenkreis gehören zu den häufigsten psychischen Erkrankungen.

  • Die medikamentöse Therapie mit Antipsychotika ist ein essenzieller Bestandteil der Akut- und Langzeitbehandlung.

  • Leitlinien geben keine eindeutigen Empfehlungen bezüglich Dauer und Dosierung von Antipsychotika in der Langzeittherapie.

  • Generell ist das Rückfallrisiko unter Medikation geringer, wobei regelmäßig eventuelle Nebenwirkungen überwacht werden müssen.

  • Ein abruptes Absetzen der Medikation sollte unbedingt vermieden werden.

  • Reduktionsversuche sollten nur in kleinen Schritten und im Verlauf von Monaten erfolgen.

  • Zusätzliche psychosoziale Interventionen reduzieren das Rückfallrisiko.

Schlüsselwörter

Antipsychotika - Dosisreduktion - Rückfallrisiko - Recovery - Depotmedikation - Nebenwirkungen


Publication History

Article published online:
11 November 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Gaebel W, Stricker J, Riesbeck M. The long-term antipsychotic treatment of schizophrenia: A selective review of clinical guidelines and clinical case examples. Schizophr Res 2020; 225: 4-14
    CrossrefPubMedSearch in Google Scholar
  • 2 Kassebaum NJ, Arora M, Barber RM. et al. Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. The Lancet 2016; 388: 1603-1658
    CrossrefPubMedSearch in Google Scholar
  • 3 Hjorthøj C, Stürup AE, McGrath JJ. et al. Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. Lancet Psychiatry 2017; 4: 295-301
    CrossrefPubMedSearch in Google Scholar
  • 4 Haukka J, Suvisaari J, Lönnqvist J. Fertility of patients with schizophrenia, their siblings, and the general population: a cohort study from 1950 to 1959 in Finland. Am J Psychiatry 2003; 160: 460-463
    CrossrefPubMedSearch in Google Scholar
  • 5 Davidson M, Kapara O, Goldberg S. et al. A nation-wide study on the percentage of schizophrenia and bipolar disorder patients who earn minimum wage or above. Schizophr Bull 2016; 42: 443-447
    CrossrefPubMedSearch in Google Scholar
  • 6 RKI, Destatis. Krankheitskosten für Deutschland für das Jahr 2015 nach Alter und Geschlecht. Statistisches Bundesamt. 2017 Accessed August 30, 2021 at: https://www.destatis.de/DE/Themen/Gesellschaft-Umwelt/Gesundheit/Krankheitskosten/_inhalt.html
    PubMedSearch in Google Scholar
  • 7 Kortmann L-M, Müller D, Simic D. et al. Disability Pension and Productivity Loss in Schizophrenia – An Empirical Analysis of the Financial Burden in Germany. Psychiatr Prax 2017; 44: 93-98
    Thieme ConnectPubMedSearch in Google Scholar
  • 8 Frey S. The economic burden of schizophrenia in Germany: a population-based retrospective cohort study using genetic matching. Eur Psychiatry 2014; 29: 479-489
    CrossrefPubMedSearch in Google Scholar
  • 9 Robinson D, Woerner MG, Alvir JM. et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999; 56: 241-247
    CrossrefPubMedSearch in Google Scholar
  • 10 Delay J, Deniker P. Neuroleptic effects of chlorpromazine in therapeutics of neuropsychiatry. Int Rec Med Gen Pract Clin 1955; 168: 318-326
    PubMedSearch in Google Scholar
  • 11 Carlsson A, Lindqvist M. Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol (Copenh) 1963; 20: 140-144
    CrossrefPubMedSearch in Google Scholar
  • 12 Huhn M, Nikolakopoulou A, Schneider-Thoma J. et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: A systematic review and network meta-analysis. The Lancet 2019; 394: 939-951
    CrossrefPubMedSearch in Google Scholar
  • 13 Ceraso A, Lin JJ, Schneider-Thoma J. et al. Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev 2020; 2020
    CrossrefPubMedSearch in Google Scholar
  • 14 Correll CU, Rubio JM, Kane JM. What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?. World Psychiatry 2018; 17: 149-160
    CrossrefPubMedSearch in Google Scholar
  • 15 Andreasen NC, Carpenter WT, Kane JM. et al. Remission in schizophrenia: proposed criteria and rationale for consensus. AJP 2005; 162: 441-449
    CrossrefPubMedSearch in Google Scholar
  • 16 Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261-275
    Search in Google Scholar
  • 17 Leucht S, Lasser R. The concepts of remission and recovery in schizophrenia. Pharmacopsychiatry 2006; 39: 161-170
    Thieme ConnectPubMedSearch in Google Scholar
  • 18 Liberman R, Kopelowicz A, Ventura J. et al. Operational criteria and factors related to recovery from schizophrenia. Int Rev Psychiatry 2002; 14: 256-272
    CrossrefSearch in Google Scholar
  • 19 Andresen R, Oades L, Caputi P. The experience of recovery from schizophrenia: towards an empirically validated stage model. Aust NZ J Psychiatry 2003; 37: 586-594
    CrossrefPubMedSearch in Google Scholar
  • 20 Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?. Arch Gen Psychiatry 2007; 64: 1123-1131
    CrossrefPubMedSearch in Google Scholar
  • 21 Correll CU, Solmi M, Veronese N. et al. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry 2017; 16: 163-180
    Search in Google Scholar
  • 22 Tiihonen J, Mittendorfer-Rutz E, Torniainen M. et al. Mortality and cumulative exposure to antipsychotics, antidepressants, and benzodiazepines in patients with schizophrenia: An observational follow-up study. Am J Psychiatry 2016; 173: 600-606
    CrossrefPubMedSearch in Google Scholar
  • 23 Torrey EF. Surviving schizophrenia: a manual for families, consumers, and providers. 4th ed. New York: Quill; 2001
    Search in Google Scholar
  • 24 Tiihonen J, Tanskanen A, Taipale H. 20-year nationwide follow-up study on discontinuation of antipsychotic treatment in first-episode schizophrenia. Am J Psychiatry 2018; 175: 765-773
    CrossrefPubMedSearch in Google Scholar
  • 25 Takeuchi H, Siu C, Remington G. et al. Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia. Neuropsychopharmacol 2019; 44: 1036-1042
    CrossrefPubMedSearch in Google Scholar
  • 26 Emsley R, Asmal L, Rubio JM. et al. Predictors of psychosis breakthrough during 24 months of long-acting antipsychotic maintenance treatment in first episode schizophrenia. Schizophr Res 2020; 225: 55-62
    CrossrefPubMedSearch in Google Scholar
  • 27 Laursen TM, Wahlbeck K, Hällgren J. et al. Life expectancy and death by diseases of the circulatory system in patients with bipolar disorder or schizophrenia in the Nordic countries. PLOS ONE 2013; 8: e67133
    CrossrefPubMedSearch in Google Scholar
  • 28 Torniainen M, Mittendorfer-Rutz E, Tanskanen A. et al. Antipsychotic treatment and mortality in schizophrenia. Schizophr Bull 2015; 41: 656-663
    CrossrefPubMedSearch in Google Scholar
  • 29 Rubio JM, Schoretsanitis G, John M. et al. Psychosis relapse during treatment with long-acting injectable antipsychotics in individuals with schizophrenia-spectrum disorders: an individual participant data meta-analysis. Lancet Psychiatry 2020; 7: 749-761
    CrossrefPubMedSearch in Google Scholar
  • 30 Harrow M, Jobe TH, Faull RN. et al. A 20-year multi-followup longitudinal study assessing whether antipsychotic medications contribute to work functioning in schizophrenia. Psychiatry Res 2017; 256: 267-274
    CrossrefPubMedSearch in Google Scholar
  • 31 Wunderink L, Nienhuis FJ, Sytema S. et al. Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome. J Clin Psychiatry 2007; 68: 654-661
    CrossrefPubMedSearch in Google Scholar
  • 32 Wunderink L, Nieboer RM, Wiersma D. et al. Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial. JAMA Psychiatry 2013; 70: 913-920
    CrossrefPubMedSearch in Google Scholar
  • 33 Ran M-S, Weng X, Chan CL-W. et al. Different outcomes of never-treated and treated patients with schizophrenia: 14-year follow-up study in rural China. Br J Psychiatry 2015; 207: 495-500
    CrossrefPubMedSearch in Google Scholar
  • 34 Gaebel W, Hasan A, Falkai P. S3-Leitlinie Schizophrenie. Berlin [Heidelberg]: Springer; 2019
    CrossrefSearch in Google Scholar
  • 35 Taipale H, Tanskanen A, Mehtälä J. et al. 20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20). World Psychiatry 2020; 19: 61-68
    CrossrefPubMedSearch in Google Scholar
  • 36 Kane JM, Kishimoto T, Correll CU. Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. World Psychiatry 2013; 12: 216-226
    CrossrefPubMedSearch in Google Scholar
  • 37 Higgins JPT, Welton NJ. Network meta-analysis: A norm for comparative effectiveness?. Lancet 2015; 386: 628-630
    CrossrefPubMedSearch in Google Scholar
  • 38 Schneider-Thoma J, Chalkou K, Dörries C. et al. Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis. The Lancet 2022; 399: 824-836
    CrossrefPubMedSearch in Google Scholar
  • 39 Alvarez-Jimenez M, Priede A, Hetrick SE. et al. Risk factors for relapse following treatment for first episode psychosis: a systematic review and meta-analysis of longitudinal studies. Schizophr Res 2012; 139: 116-128
    CrossrefPubMedSearch in Google Scholar
  • 40 Misawa F, Kishimoto T, Hagi K. et al. Safety and tolerability of long-acting injectable versus oral antipsychotics: A meta-analysis of randomized controlled studies comparing the same antipsychotics. Schizophr Res 2016; 176: 220-230
    CrossrefPubMedSearch in Google Scholar
  • 41 Kishimoto T, Hagi K, Kurokawa S. et al. Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies. Lancet Psychiatry 2021; 8: 387-404
    CrossrefPubMedSearch in Google Scholar
  • 42 Houston MC, Hodge R. Beta-adrenergic blocker withdrawal syndromes in hypertension and other cardiovascular diseases. Am Heart J 1988; 116: 515-523
    CrossrefPubMedSearch in Google Scholar
  • 43 Silvestri S, Seeman MV, Negrete JC. et al. Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study. Psychopharmacol (Berl) 2000; 152: 174-180
    CrossrefPubMedSearch in Google Scholar
  • 44 Chouinard G, Samaha A-N, Chouinard V-A. et al. Antipsychotic-induced dopamine supersensitivity psychosis: Pharmacology, criteria, and therapy. Psychother Psychosom 2017; 86: 189-219
    CrossrefPubMedSearch in Google Scholar
  • 45 Meltzer HY, Lee MA, Ranjan R. et al. Relapse following clozapine withdrawal: effect of neuroleptic drugs and cyproheptadine. Psychopharmacol (Berl) 1996; 124: 176-187
    CrossrefPubMedSearch in Google Scholar
  • 46 Schneider-Thoma J, Chalkou K, Dörries C. et al. Comparative efficacy and tolerability of 31 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis. Lancet 2022; 399: 824-836
    CrossrefPubMedSearch in Google Scholar
  • 47 Schneider-Thoma J, Efthimiou O, Bighelli I. et al. Second-generation antipsychotic drugs and short-term somatic serious adverse events: a systematic review and meta-analysis. Lancet Psychiatry 2019; 6: 753-765
    CrossrefPubMedSearch in Google Scholar
  • 48 Ray WA, Chung CP, Murray KT. et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009; 360: 225-235
    CrossrefPubMedSearch in Google Scholar
  • 49 Salimi K, Jarskog LF, Lieberman JA. Antipsychotic drugs for first-episode schizophrenia: a comparative review. CNS Drugs 2009; 23: 837-855
    CrossrefPubMedSearch in Google Scholar
  • 50 Tek C, Kucukgoncu S, Guloksuz S. et al. Antipsychotic-induced weight gain in first-episode psychosis patients: a meta-analysis of differential effects of antipsychotic medications. Early Intervention in Psychiatry 2016; 10: 193-202
    CrossrefPubMedSearch in Google Scholar
  • 51 Takeuchi H, Suzuki T, Remington G. et al. Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: an open-label, randomized, controlled, pilot study. Schizophr Bull 2013; 39: 993-998
    CrossrefPubMedSearch in Google Scholar
  • 52 Zhang W, Deng W, Yao L. et al. Brain structural abnormalities in a group of never-medicated patients with long-term schizophrenia. Am J Psychiatry 2015; 172: 995-1003
    CrossrefPubMedSearch in Google Scholar
  • 53 Andreasen NC, Liu D, Ziebell S. et al. Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study. Am J Psychiatry 2013; 170: 609-615
    CrossrefPubMedSearch in Google Scholar
  • 54 Emsley R, Asmal L, du Plessis S. et al. Brain volume changes over the first year of treatment in schizophrenia: relationships to antipsychotic treatment. Psychol Med 2017; 47: 2187-2196
    CrossrefPubMedSearch in Google Scholar
  • 55 Leucht S, Bauer S, Siafis S. et al. Examination of dosing of antipsychotic drugs for relapse prevention in patients with stable schizophrenia: A meta-analysis. JAMA Psychiatry 2021; 78: 1238-1248
    CrossrefPubMedSearch in Google Scholar
  • 56 Leucht S, Tardy M, Komossa K. et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 2012; 379: 2063-2071
    CrossrefPubMedSearch in Google Scholar
  • 57 Bogers JPAM, Hambarian G, Michiels M. et al. Risk factors for psychotic relapse after dose reduction or discontinuation of antipsychotics in Patients with chronic schizophrenia: A systematic review and meta-analysis. Schizophr Bull Open 2020; 1: sgaa002
    CrossrefSearch in Google Scholar
  • 58 Sampson S, Mansour M, Maayan N. et al. Intermittent drug techniques for schizophrenia. Cochrane Database Syst Rev 2013;
    CrossrefPubMedSearch in Google Scholar
  • 59 Kane JM, Davis JM, Schooler N. et al. A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia. Am J Psychiatry 2002; 159: 554-560
    CrossrefPubMedSearch in Google Scholar
  • 60 Huhn M, Leucht C, Rothe P. et al. Reducing antipsychotic drugs in stable patients with chronic schizophrenia or schizoaffective disorder: a randomized controlled pilot trial. Eur Arch Psychiatry Clin Neurosci 2021; 271: 293-302
    CrossrefPubMedSearch in Google Scholar
  • 61 Horowitz MA, Jauhar S, Natesan S. et al. A method for tapering antipsychotic treatment that may minimize the risk of relapse. Schizophr Bull 2021; 47: 1116-1129
    CrossrefPubMedSearch in Google Scholar
  • 62 Jääskeläinen E, Juola P, Hirvonen N. et al. A systematic review and meta-analysis of recovery in schizophrenia. Schizophr Bull 2013; 39: 1296-1306
    CrossrefPubMedSearch in Google Scholar
  • 63 Bighelli I, Rodolico A, García-Mieres H. et al. Psychosocial and psychological interventions for relapse prevention in schizophrenia: a systematic review and network meta-analysis. Lancet Psychiatry 2021; 8: 969-980
    CrossrefPubMedSearch in Google Scholar
  • 64 Alvarez-Jimenez M, Koval P, Schmaal L. et al. The Horyzons project: a randomized controlled trial of a novel online social therapy to maintain treatment effects from specialist first-episode psychosis services. World Psychiatry 2021; 20: 233-243
    CrossrefPubMedSearch in Google Scholar